Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $107.00. Dolezal covers the Healthcare sector, focusing on ...
A multinational research team has revealed how a tryptophan-rich allosteric communication network regulates receptor dynamics ...
Structure Therapeutics (NASDAQ:GPCR) shared new top-line results from its ACCESS II clinical program for aleniglipron, an ...
Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.
Commercial sales and marketing agreement enhances 3RnD’s mechanistic toxicity screening panel, and expands the reach of ...
A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...
A multidisciplinary team of researchers from the Hangzhou-based Zhejiang University have made a major breakthrough in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results